Papers
5
Total Citations
62
H-Index
5
About
S. De Vergie is a leading urologic oncologist whose work centers on advancing minimally invasive surgical techniques for testicular and kidney cancers. Their major contributions include pioneering the safety and feasibility of minimally invasive retroperitoneal lymph node dissection for testis cancer, a procedure that reduces recovery time while maintaining oncologic rigor, as detailed in their 2022 study (27 citations). In kidney cancer, De Vergie led the NEPRAH study (UroCCR 175), a multicentre prospective cohort comparing robot-assisted partial nephrectomy for hilar versus nonhilar renal masses, demonstrating comparable perioperative and functional outcomes (15 citations). They also co-authored the 2024–2026 French AFU Cancer Committee Guidelines for kidney cancer management, synthesizing evidence from 2014–2024 to shape national treatment standards (10 citations). Notably, De Vergie is spearheading the ACCURATE clinical trial (UroCCR 99), a randomized study evaluating three-dimensional image-guided robot-assisted partial nephrectomy for complex renal tumors, set to define future surgical precision. Their work, accumulating over 60 citations, bridges surgical innovation with evidence-based guidelines, directly impacting patient care and training the next generation of urologic surgeons.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5